Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

31.99 -0.34 (-1.05%)
Streaming Delayed Price Updated: 12:30 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT on track to initiate trial this year 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports First Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.